2025
Systemic in utero gene editing as a treatment for cystic fibrosis
Ricciardi A, Barone C, Putman R, Quijano E, Gupta A, Nguyen R, Mandl H, Piotrowski-Daspit A, Lopez-Giraldez F, Luks V, Freedman-Weiss M, Farrelly J, Ahle S, Lynn A, Glazer P, Saltzman W, Stitelman D, Egan M. Systemic in utero gene editing as a treatment for cystic fibrosis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2418731122. PMID: 40493185, PMCID: PMC12184489, DOI: 10.1073/pnas.2418731122.Peer-Reviewed Original ResearchConceptsUtero gene editingCystic fibrosisCF transmembrane conductance regulatorTreat CF patientsTransmembrane conductance regulatorWild-type miceIrreversible organ damageNormal organ developmentTreat monogenic diseasesCFTR activityCF patientsConductance regulatorDisease-causing genesMultiorgan diseaseDisease improvementOrgan damageGene editingMonogenic diseasesMutation correctionPolymeric nanoparticlesGastrointestinal tissuesDiseaseBirthFibrosisReproductive systemMeasurement of Blood Pressure in Children and Adolescents Outside the Office for the Diagnosis of Hypertension
Nugent J. Measurement of Blood Pressure in Children and Adolescents Outside the Office for the Diagnosis of Hypertension. Current Cardiology Reports 2025, 27: 27. PMID: 39826056, DOI: 10.1007/s11886-024-02178-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAmbulatory blood pressure monitoringBlood pressure monitoringHome blood pressure monitoringDiagnosis of hypertensionBlood pressurePressure monitoringUsefulness of ambulatory blood pressure monitoringOffice blood pressureOut-of-office blood pressure measurementsTarget organ damageNovel care pathwayHome blood pressureMeasurement of blood pressureBlood pressure measurementsOrgan damageHypertensionHypertension statusSubspecialty settingsCare pathwaysDiagnosis
2024
An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia
Cai Y, Jiang H, Li T, Luo D, Li P, Wang Y. An unusual case of primary melioidotic prostatic disease: Misdiagnosed as benign prostatic hyperplasia. Heliyon 2024, 10: e37906. PMID: 39323819, PMCID: PMC11422042, DOI: 10.1016/j.heliyon.2024.e37906.Peer-Reviewed Original ResearchBenign prostatic hyperplasiaProstate diseaseProstatic hyperplasiaBurkholderia pseudomallei</i>.Urine culturePulmonary infectionTrimethoprim-sulfamethoxazoleSurvival rate of patientsTreated with imipenemUrinary tract infectionAnti-infective treatmentRate of patientsHistory of hypertensionYear old maleMultiple organ damageProstatic abscessTract infectionsInflammatory markersClinical manifestationsCure rateUnusual caseFatal infectious diseaseOrgan damageDifficulty urinatingSurvival rateSPIKENET: An Evidence-Based Therapy for Long COVID
Elumalai N, Hussain H, Sampath N, Shamaladevi N, Hajjar R, Druyan B, Rashed A, Ramamoorthy R, Kenyon N, Jayakumar A, Paidas M. SPIKENET: An Evidence-Based Therapy for Long COVID. Viruses 2024, 16: 838. PMID: 38932130, PMCID: PMC11209161, DOI: 10.3390/v16060838.Peer-Reviewed Original ResearchCarcinoembryonic antigen-related cell adhesion molecule 1Murine hepatitis virus-1Post-acute sequelae of COVID-19SARS-CoV-2 variantsSARS-CoV-2Development of severe inflammationCell adhesion molecule 1Long-term complicationsAdhesion molecule 1Multiple organ damagePotential therapeutic benefitMultiple SARS-CoV-2 variantsEvidence-based therapiesSequelae of COVID-19ACE2 receptor-binding domainSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Severe inflammationTissue edemaOrgan damageRespiratory syndrome coronavirus 2Long COVIDMolecule 1Receptor-binding domainSyndrome coronavirus 2Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samples
2023
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsImmune-related adverse eventsPre-existing autoimmune diseaseAutoimmune diseasesCheckpoint inhibitorsFlare-upBenefit of immune checkpoint inhibitorsAutoimmune disease flare-upManagement of flare-upsPre-existing autoimmune disordersImmune checkpoint inhibitor treatmentCancer CenterDisease flare-upContext of autoimmune diseasesAutoimmune disease progressionAutoimmune disease treatmentAutoimmune disordersAdverse eventsTreatment modificationOrgan damageComprehensive cancer centerDisease progressionPatientsCancerUS cancer centersDysregulated MicroRNAs in the Pathogenesis of Systemic Lupus Erythematosus: A Comprehensive Review
Choi D, Kim J, Yang J, Kim J, Park S, Shin J. Dysregulated MicroRNAs in the Pathogenesis of Systemic Lupus Erythematosus: A Comprehensive Review. International Journal Of Biological Sciences 2023, 19: 2495-2514. PMID: 37215992, PMCID: PMC10197884, DOI: 10.7150/ijbs.74315.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLupus erythematosusPathogenesis of systemic lupus erythematosusComparison to healthy controlsPathogenesis of lupusSevere renal diseaseChronic autoimmune diseaseClinical presentationLupus patientsPotential roleDisease activitySLE pathogenesisAutoimmune diseasesOrgan damageRenal diseaseHealthy controlsPathogenic roleTherapeutic potentialTreatment goalsGenetic factorsPathogenesisPathogenic processesErythematosusEpigenetic factorsLupusSmooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia
Biwer L, Lu Q, Ibarrola J, Stepanian A, Man J, Carvajal B, Camarda N, Zsengeller Z, Skurnik G, Seely E, Karumanchi S, Jaffe I. Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia. Circulation Research 2023, 132: 674-689. PMID: 36815487, PMCID: PMC10119809, DOI: 10.1161/circresaha.122.321228.Peer-Reviewed Original ResearchConceptsBlood pressureSMC-MRHypertensive stimuliBP responseSmooth Muscle Cell Mineralocorticoid ReceptorsAngII type 1 receptorType 1 receptor expressionMR transcriptional activityIncreased cardiovascular riskElevated blood pressureEnd-organ damageHigh salt intakeHigh blood pressureRisk of hypertensionType 1 receptorSoluble VEGF receptorAngII infusionPrior preeclampsiaMR antagonismCardiovascular riskNormotensive pregnanciesSalt dietAortic stiffnessSalt intakeOrgan damage
2022
Effect of intravenous antihypertensives on outcomes of severe hypertension in hospitalized patients without acute target organ damage
Ghazi L, Li F, Simonov M, Yamamoto Y, Nugent J, Greenberg J, Bakhoum C, Peixoto A, Wilson F. Effect of intravenous antihypertensives on outcomes of severe hypertension in hospitalized patients without acute target organ damage. Journal Of Hypertension 2022, 41: 288-294. PMID: 36583354, PMCID: PMC9799038, DOI: 10.1097/hjh.0000000000003328.Peer-Reviewed Original ResearchConceptsAcute target organ damageTarget organ damageSevere hypertensionOrgan damageIntravenous antihypertensivesBP elevationClinical outcomesMyocardial injuryTarget end-organ damageOverlap propensity scoreSevere BP elevationAcute kidney injuryBlood pressure reductionEnd-organ damageRisk of strokeInpatient hypertensionCardiovascular eventsIndex hospitalizationKidney injuryRetrospective studyHypertensionAntihypertensivesHospitalizationCox modelPatientsCoronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study
Cainzos‐Achirica M, Quispe R, Mszar R, Dudum R, Al Rifai M, Erbel R, Stang A, Jöckel K, Lehmann N, Schramm S, Schmidt B, Toth P, Rana J, Lima J, de Vasconcellos H, Lloyd‐Jones D, Joshi P, Ayers C, Khera A, Blaha M, Greenland P, Nasir K. Coronary Artery Calcium Score to Refine the Use of PCSK9i in Asymptomatic Individuals: A Multicohort Study. Journal Of The American Heart Association 2022, 11: e025737. PMID: 35943062, PMCID: PMC9496288, DOI: 10.1161/jaha.122.025737.Peer-Reviewed Original ResearchConceptsLow-density lipoprotein cholesterol levelsCoronary artery calciumAtherosclerotic cardiovascular diseaseLipoprotein cholesterol levelsClinically evident atherosclerotic cardiovascular diseaseSubclinical organ damageTraditional risk factorsHigh-risk scenariosRisk factorsAssociated with ASCVD eventsCholesterol levelsOrgan damageASCVD event ratesAtherosclerotic cardiovascular disease riskCoronary Artery Calcium TestingLow-density lipoprotein cholesterol <Coronary artery calcium scoreCoronary artery calcium burdenArtery calcium scoreASCVD eventsCalcium scoreArtery calciumFamilial hypercholesterolemiaPCSK9iMulticohort studyAre there sex differences in risk for exertional heat stroke? A translational approach
Giersch GEW, Garcia CK, Stachenfeld N, Charkoudian N. Are there sex differences in risk for exertional heat stroke? A translational approach. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2022, 107: 1136-1143. PMID: 35598159, DOI: 10.1113/ep090402.Peer-Reviewed Original ResearchConceptsExertional heat strokeHeat strokeRisk factorsTranslational approachCentral nervous system dysfunctionNervous system dysfunctionFemale sex hormonesSex differencesHuman researchOrgan damageFatal conditionSystem dysfunctionSex hormonesPhysical activityStrokeTranslational modelOccupational workersRiskMilitary personnelAnimalsTreatmentHuman modelReviewFuture investigationsPhysiological differencesManifestations of Sickle Cell Disorder at Abdominal and Pelvic Imaging.
Solomon N, Segaran N, Badawy M, Elsayes KM, Pellerito JS, Katz DS, Moshiri M, Revzin MV. Manifestations of Sickle Cell Disorder at Abdominal and Pelvic Imaging. RadioGraphics 2022, 42: 1103-1122. PMID: 35559660, DOI: 10.1148/rg.210154.Peer-Reviewed Educational MaterialsConceptsSickle cell disordersMultisystem organ damageCharacteristic clinical syndromeTreatment of patientsPelvic imaging studiesDiagnosis of patientsSickle-shaped red blood cellsEvaluation of manifestationsPelvic manifestationsFunctional aspleniaRed blood cellsClinical presentationOrgan damageOrgan ischemiaSCD complicationsClinical syndromeRecurrent episodesUncommon sequelaVascular occlusionImaging featuresHematologic disordersDisease manifestationsIllness leadCell disordersOnline supplemental material
2021
Hematopoietic cell transplantation for sickle cell disease: updates and future directions
Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease: updates and future directions. Hematology 2021, 2021: 181-189. PMID: 34889368, PMCID: PMC8791142, DOI: 10.1182/hematology.2021000251.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseCell transplantationAlternative donorsCell diseaseOutcomes of HCTHLA-identical related donorsSymptomatic sickle cell diseaseNew disease-modifying drugsHost disease (GVHD) prophylaxisHLA-identical siblingsAvailable therapeutic optionsDisease-modifying drugsLong-term outcomesCord blood expansionConditioning regimensDisease prophylaxisRelated donorsOrgan damageHematopoietic progenitor cellsTherapeutic optionsExcellent outcomesCareful counselingAutologous transplantationClinical registryAn update: the emerging evidence of complement involvement in COVID-19
Li Q, Chen Z. An update: the emerging evidence of complement involvement in COVID-19. Medical Microbiology And Immunology 2021, 210: 101-109. PMID: 33811541, PMCID: PMC8019074, DOI: 10.1007/s00430-021-00704-7.Peer-Reviewed Original ResearchConceptsAcute respiratory distress syndromeCOVID-19 patientsCOVID-19Pre-clinical samplesRespiratory distress syndromePotential treatment optionCoronavirus disease 2019Host immune responseMultiorgan failureComplement involvementSystemic inflammationDistress syndromeSevere patientsOrgan damageKidney failureTreatment optionsInflammatory responseTissue injuryDisease 2019Immune responseAnimal modelsMultiple organsAbnormal activationInnate immunityComplement inhibitors
2020
An in vivo atlas of host–pathogen transcriptomes during Streptococcus pneumoniae colonization and disease
D’Mello A, Riegler AN, Martínez E, Beno SM, Ricketts TD, Foxman EF, Orihuela CJ, Tettelin H. An in vivo atlas of host–pathogen transcriptomes during Streptococcus pneumoniae colonization and disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 2020, 117: 33507-33518. PMID: 33318198, PMCID: PMC7777036, DOI: 10.1073/pnas.2010428117.Peer-Reviewed Original ResearchConceptsStreptococcus pneumoniae colonizationHost gene expression profilesHost defense pathwaysOrgan damagePneumoniae colonizationProinflammatory responseInvasive diseaseAnatomical sitesTherapeutic targetInterferon responseDisease statesDiseaseGene expression profilesLungOrgan-specific mannerVivoPneumoniaPathogenesisKidneyBloodResponseGeriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: A systematic review
Mohamadi M, Goodarzi A, Aryannejad A, Fattahi N, Alizadeh-Khoei M, Miri S, Hekmat H, Payab M, Bodaghabadi M. Geriatric challenges in the new coronavirus disease-19 (COVID-19) pandemic: A systematic review. Medical Journal Of The Islamic Republic Of Iran 2020, 34: 123-123. PMID: 33437719, PMCID: PMC7787036, DOI: 10.34171/mjiri.34.123.Peer-Reviewed Original ResearchElderly patientsSARS-CoV-2Complications of COVID-19Systematic reviewSARS-CoV-2 infectionElderly individualsEvaluate complicationsImmune system responseMultiorgan involvementSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Organ damageMOOSE guidelinesRespiratory syndrome coronavirus 2Coronavirus disease-19Pulmonary systemRenal systemPatientsPubMed databaseSyndrome coronavirus 2Relevant articlesMeSH termsCoronavirus 2Mental healthCOVID-19Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Gerds A, Gotlib J, Bose P, Deininger M, Dunbar A, Elshoury A, George T, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall A, McMahon B, Mohan S, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder D, Stein B, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward D, Bergman M, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2020, 18: 1248-1269. PMID: 32886902, DOI: 10.6004/jnccn.2020.0042.Peer-Reviewed Original ResearchConceptsMyeloid/lymphoid neoplasmsWHO classificationMLN-EoFusion geneEosinophilic disordersNCCN Clinical Practice GuidelinesRearrangement of PDGFRATyrosine kinaseABL1 rearrangementsClinical practice guidelinesLymphoid neoplasmsNCCN guidelinesDysregulated tyrosine kinasePeripheral bloodPCM1-JAK2Organ damageABL1 geneNonneoplastic conditionsNeoplasmsEosinophiliaHeterogeneous groupFLT3Practice guidelinesNCCNABL1Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits
Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review Of Hematology 2020, 13: 489-499. PMID: 32248712, DOI: 10.1080/17474086.2020.1751609.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWhite blood cell countAcute myeloid leukemiaTumor lysis syndromeMyeloid leukemiaPeripheral white blood cell countEvidence-based clinical guidelinesTotal white blood cell countEnd-organ damageRelevant patient outcomesWide practice variationBlood cell countPeripheral myeloblastsLysis syndromeIntravascular coagulationSurvival benefitOrgan damageClinical guidelinesPatient outcomesPractice variationLeukocytapheresisHigh riskCytoreductive strategyCell countHyperleukocytosisCells/L
2019
Long-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome
Awadie H, Khoury J, Zohar Y, Yaccob A, Veitsman E, Saadi T. Long-term Follow-up of Severe Eosinophilic Hepatitis: A Rare Presentation of Hypereosinophilic Syndrome. Rambam Maimonides Medical Journal 2019, 10: e0020. PMID: 31335311, PMCID: PMC6649775, DOI: 10.5041/rmmj.10373.Peer-Reviewed Original ResearchHypereosinophilic syndromeIdiopathic hypereosinophilic syndromeLiver involvementLong-term follow-upIsolated liver involvementSolid organ involvementRare systemic diseaseEnd-organ damageIntensive immunosuppressive treatmentAdvanced liver failureHigher eosinophil countsEosinophilic hepatitisImmunosuppressive treatmentChronic hepatitisLiver dysfunctionOrgan involvementLiver biopsyLiver failureEosinophil countOrgan damageRare presentationSystemic diseaseFollow-upAppropriate treatmentLow doseCurative Therapies for Sickle Cell Disease.
Khemani K, Katoch D, Krishnamurti L. Curative Therapies for Sickle Cell Disease. Ochsner Journal 2019, 19: 131-137. PMID: 31258425, PMCID: PMC6584191, DOI: 10.31486/toj.18.0044.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseHaploidentical donorsSibling donorsCurative therapyUnrelated donorsCell diseaseHLA-identical sibling donorsRelated haploidentical donorsEvent-free survivalIdentical sibling donorsBone marrow transplantationStem cell transplantationAmelioration of symptomsHuman leukocyte antigenComparative clinical trialsGene therapyUse of HLAStable long-term engraftmentLong-term engraftmentMarrow transplantationRelated donorsSevere morbidityCurative treatmentOrgan damage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply